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INTRODUCTION: Early myoclonus after Cardiac Arrest (CA) is traditionally viewed as a 30 
poor prognostic sign (status myoclonus). However, some patients may present early 31 
Lance-Adams syndrome (LAS): under appropriate treatment, they can reach a 32 
satisfactory functional outcome. Our aim was to describe their profile, focusing on 33 
pharmacologic management in the ICU, time to return of awareness, and long-term 34 
prognosis.  35 
METHODS: Adults with early LAS (defined as generalized myoclonus within 96 hours, 36 
with epileptiform EEG within 48 hours after CA) were retrospectively identified in our CA 37 
registry between 2006 and 2016. Functional outcome was assessed through Cerebral 38 
Performance Categories (CPC) at three months, CPC 1-2 defined good outcome.  39 
RESULTS: Among 458 consecutive patients, 7 (1.5%) developed early LAS (4 women, 40 
median age 59 years). Within 72 hours after CA, in normothemia and off sedation, all 41 
showed preserved brainstem reflexes and localized pain. All patients were initially 42 
treated with valproate, levetiracetam and clonazepam; additional agents, including 43 
propofol and midazolam, were prescribed in the majority. First signs of awareness 44 
occurred after 3-23 days (median 11.8); 3/7 reached a good outcome at three months. 45 
CONCLUSION: Early after CA, myoclonus together with a reactive, epileptiform EEG, 46 
preserved evoked potentials and brainstem reflexes suggests LAS. This condition was 47 
managed with a combination of highly dosed, large spectrum antiepileptic agents 48 
including propofol and midazolam. Even if awakening was at times delayed, good 49 
outcome occurred in a substantial proportion of patients. 50 
 51 
 52 
 53 
 54 
 55 
INTRODUCTION:  56 
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Nearly one fifth of patients resuscitated from cardiac arrest (CA) may develop 57 
myoclonus 1, 2. However, clinical and electroencephalographic (EEG) differences exist 58 
between “status myoclonus”, a condition strongly related to poor prognosis 3, and 59 
myoclonus that is amenable to improvement, including awakening with awareness, 60 
which may represent early-appearing Lance-Adams syndrome (LAS)2, 4, 5. The latter has 61 
been defined as generalized action myoclonus appearing within a few days to weeks 62 
after CA and coma, mostly (but not exclusively) of hypoxic origin 6. It is often 63 
accompanied by dysmetria, dysarthria and ataxia, with relative preservation of cognition 64 
7. This syndrome can become chronic, and patients usually need long-term antiepileptic 65 
treatment. Specific EEG features in patients with early myoclonus have been recently 66 
outlined 4: suppression-burst background with high-amplitude, diffuse polyspikes 67 
correlate with dismal prognosis (“status myoclonus”), whereas continuous background 68 
with narrow, midline centered spike-waves correspond to LAS, and a relatively good 69 
outcome.  70 
Clinically, it is of paramount importance to recognize early LAS patients in order to offer 71 
them a chance of regaining awareness. Our aim was to describe our experience, 72 
focusing on pharmacologic management in the ICU, time to awakening, and long-term 73 
prognosis. 74 
 75 
METHODS:  76 
Patients: From our prospective CA registry including consecutive adults admitted for CA 77 
from June 2006 to November 2016, we retrospectively identified subjects with early LAS  78 
defined as follows: survivors at discharge, having presented generalized myoclonus 79 
within 96 hours after CA (considering the masking effect of acute sedation) together with 80 
an epileptiform EEG on a continuous background within 48 hours 4.  81 
Until July 2014, patients were managed at 33° during the first 24 hours, then 82 
increasingly at 36°C. Sedation/analgesia during targeted temperature management 83 
(TTM) in either approaches consisted of intravenous infusions of midazolam 84 
(0.1mg/Kg/h), or 2% propofol (2mg/kg/h), with fentanyl (1.5 µg/kg/h). Rocuronium 85 
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boluses were used for shivering prevention 2. Sedation is routinely weaned within 36 86 
hours after CA. The registry is approved by our Ethic’s commission. 87 
Data collection: Following variables were entered prospectively in the registry: 88 
demographics, CA type (ventricular fibrillation, versus asystole or pulseless electrical 89 
activity), aetiology (cardiac versus respiratory, or unknown), time to return of 90 
spontaneous circulation (ROSC), brainstem reflexes (pupillary, oculocephalic, corneal) 91 
within 72 hours following CA, serum neuron-specific (NSE), and time of EEG and 92 
somatosensory evoked potentials (SSEP) recording. Outcome was assessed at 3 93 
months using a semi-structured phone interview  using  the Glasgow-Pittsburgh 94 
Cerebral Performance Categories (CPC)8, CPC 1and 2 defining good outcome. 95 
EEG and SSEP were prospectively interpreted by certified clinical neurophysiologists 96 
(JN, AOR). For this study, EEG findings were categorized as “reactive” (defined as a 97 
reproducible change in amplitude or frequency, excluding stimulus-induced rhythmic, 98 
periodic, or ictal discharges (SIRPIDs) and muscle artifacts) 9 or not, and as 99 
“epileptiform” (any repetitive periodic or rhythmic spikes, or sharp waves, or spike-100 
waves) or not 10. NSE was repetitively analyzed with an automated immunofluorescent 101 
assay (Thermo Scientific Brahms NSE Kryptor Immunoassay, Henningsdorf, Germany). 102 
For the present analysis we considered peak values within 48 hours after CA.  103 
We retrospectively retrieved antiepileptic drugs (AEDs) used within 10 days following 104 
CA, including daily dosages and their trough blood values, if tested; time to first 105 
myoclonus occurrence, and to first signs of awareness (interaction with the environment 106 
including targeted response on demand, and prolonged eye tracking).  107 
 108 
RESULTS 109 
Patient characteristics: Among the 458 CA patients, seven survivors (1.5%) developed 110 
early LAS as previously defined.  111 
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Median age was 57 years, most common CA etiology was cardiac, while first cardiac 112 
rhythms were evenly distributed. Median time to ROSC was 22 minutes. Their clinical 113 
characteristics are summarized in Table 1.  114 
Neurological and neurophysiological assessments:  Within 72 hours after CA, in 115 
normothermia and off sedation, all seven patients had preserved brainstem reflexes and 116 
localized pain; only two showed spontaneous eye opening (without interaction with the 117 
environment). Clinical myoclonus appeared after a median of two days (range 1-3 days). 118 
In all subjects, cortical SSEP responses were observed, and EEG recorded without 119 
sedation (figure1) showed epileptiform activity occurring together with background 120 
reactivity. In three subjects, EEGs were also recorded under TTM and sedation: none 121 
showed epileptiform discharges, as these appeared only after sedation weaning. The 122 
median serum NSE peak value was 17.1 ng/L. 123 
Antiepileptic treatments and blood levels:  Upon observation of an epileptiform EEG, 124 
every patient received intravenous valproate (30mg/kg, then 3x600mg/d), levetiracetam 125 
(20mg/kg, then 4x500mg/d), and clonazepam (up to 2mg/d) as a first line “cocktail”, 126 
according to our protocol. Additional AED were prescribed in most patients (see Table 127 
1). All patients except one received a pharmacologic burst-suppression under 128 
continuous EEG for 24-48h with propofol (median dose 2.5mg/kg/h) and midazolam 129 
(median dose 0.18mg/kg/h). Total trough serum levels of valproate were below 130 
reference ranges in four of six tested subjects, despite high doses. However, albumine 131 
median level was 32g/L (reference: 35-52), and one patient received concomitantly 132 
meropenem. Regarding other AEDs, levels were within the reference range 133 
(levetiracetam and topiramate) or below (phenobarbital and another levetiracetam, see 134 
Table 1 for details).  135 
Outcome: The first signs of awareness appeared in median after 12 days, and in one 136 
patient were delayed up to 23 days. For comparison, median time to awakening in the 137 
last 30 consecutive patients of the registry was 2 days (1-12). At 3 months, a meaningful 138 
cognitive impairment (CPC 3) was found in four patients, while the other three achieved 139 
full recovery (CPC 1); all of them were still treated with AEDs. In two patients, 140 
reduction/interruption of AEDs several years after CA resulted in a myoclonic status 141 
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epilepticus. Of note, no other subject in the registry, regardless of survivorship, had 142 
myoclonus and epileptiform EEG after stopping sedation, occurring together with 143 
preserved EEG reactivity, brainstem reflexes and SSEP.  144 
 145 
DISCUSSION 146 
This series shows that early LAS, occurring in only 1.5% of our cohort, represents a rare 147 
diagnosis in patients after a CA. A combination of high dosed, relatively broad spectrum 148 
AED was used promptly, but the first signs of awareness were relatively delayed (up to 149 
three weeks); almost half of patients had a complete recovery.   150 
In a previous assessment of our group, including 1 patient described here, 24.8% of the 151 
cohort developed a postanoxic status epilepticus, 2 of whom had LAS (3.1% of total) 5; 152 
in another recent series, 1.9% developed LAS 4. While our patients showed myoclonic 153 
jerks early following CA, after sedation weaning, awareness recovery occurred much 154 
later. LAS can appear a few days to few weeks after injury 6, but also while the patient is 155 
still in coma 7, as we observed. Status myoclonus usually starts also early, within the 156 
first 24-48 hours following CA 11, but “resists” to sedation during targeted temperature 157 
management1. As opposed to the present series, previous reports 12, 13 described LAS 158 
developing rather in patients with respiratory causes of CA; this suggests that LAS may 159 
not be preferentially linked to a specific pathophysiology. 160 
In our cohort, antiepileptic treatment was started immediately after observing an 161 
epileptiform EEG, within 48 hours from CA. AEDs used as first line were broad-spectrum 162 
antimyoclonic agents given at relatively high doses. Additional treatments (including 163 
propofol and midazolam infusions) were necessary in all but one patient in order to 164 
control clinical myoclonus and EEG features. Total valproate serum levels were often 165 
low due to hypoalbuminemia or concomitant use of meropenem. Some case reports on 166 
LAS already mentioned treatment with clonazepam and valproate 7, 14, 15; as postanoxic 167 
myoclonus associated with epileptiform discharges is heterogeneous in terms of clinical 168 
outcome 4, treatment escalation seems reasonable in patients with features compatible 169 
with favorable prognosis in a multimodal assessment, including EEG, SSEP and NSE16. 170 
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Nevertheless, our series does not support the need of prolonged anesthetic treatment, 171 
as every patient showed improved EEGs after a first propofol/midazolam course and 172 
subsequently received non-sedative AEDs to allow awakening. Myoclonus recurrence 173 
after delayed AEDs withdrawal indicates that these patients should have a regular 174 
follow-up.  175 
These observations may allow delineating an entity whose cornerstones are a 176 
combination of epileptiform EEG appearing only after sedation weaning, together with 177 
preserved background reactivity and cortical SSEP, and recovery of brainstem reflexes. 178 
This represents a composite hallmark of possible favorable prognosis. Indeed, even in 179 
the presence of myoclonus, this multimodal assessment allows a comprehensive clinical 180 
judgment: withdrawal of ICU support should never be based upon isolated signs 16-18.  181 
This consideration seems especially pertinent in the light of delayed awakening to up to 182 
three weeks, as previously described 5, 7, 19, even longer than the longest delay reported 183 
in a recent large cohort study on CA patients20.  184 
Limitations of this study are the lack of detailed information on patients showing a similar 185 
clinical constellation but not surviving to hospital discharge, as we retrospectively 186 
identified the analyzed subjects from survivors; however, no other patients with similar 187 
clinical characteristics was identified in the registry. LAS definition for patients’ 188 
identification was based on a recent study including EEG criteria 4, and is not universally 189 
accepted. Finally, we believe our approach of aggressive antiepileptic drug treatment has good 190 
face validity. However, our results simply demonstrate that with this strategy many patients can 191 
make a good recovery. Still, it remains unknown whether aggressive treatment is superior to 192 
expectant management.  193 
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Legends:  241 
Table 1: clinical features of 7 patients with early LAS 242 
Abbreviations: M= male; F= female; VF= ventricular fibrillation; PEA= pulseless electrical 243 
activity; SR= sinus rhythm; EEG= electroencephalographic; SSEP= somatosensory 244 
evoked potentials; NSE= serum neuron specific; VS = vegetative state; VPA= valproate; 245 
LEV= levetiracetam; CLZ= clonazepam; TPM= topiramate; PER= perampanel; PB= 246 
Phenobarbital, PGB=pregabaline. 247 
Therapeutic range of AEDs serum levels: VPA= 50-100mg/L; LEV= 12-46 mg/L; TPM= 248 
5-20 mg/L; PB= 10-40 mg/L. Albumin levels 35-52 g/L 249 
 250 
 251 
Figure 1: EEG recorded 2 days after CA under levetiracetam, clonazepam and 252 
valproate, showing abundant mid-voltage sharp waves with maximum on parietal and 253 
midline regions, superimposed on an irregular theta. Upon pain stimulus, a transitory 254 
diffuse acceleration of the background is seen.” 255 
 256 
 257 
Age, 
Gender Cause 
First 
rhyht
m 
Time to 
ROSC(min
) 
EEG 
(epileptiform 
activity) (h) 
 
 
First EEG 
reactivity 
noted 
Bilaterall
y cortical 
SSEP 
Braisntem reflexes 
(pupils, 
oculocephalic, 
corneal) 
 
 
Myoclonus 
(d) 
NSE 
peak(ng/mL) 
Antiepileptic 
medication during 
first 10d 
Peak dosage during first 
10d (mg/d) 
Peak serum 
trough 
level (<10d) 
(mg/L) 
 
 
Albumine 
levels (g/L) 
Return of 
awareness 
(days after CA) 
Best CPC 3 mo. 
53, M Cardiac VF 20 48 
 
 
Yes (96h) 120h Present at 72h 
 
 
2 Not done 
A VPA 
B LEV 
 
A .1500 
B. 2000 
A. Not 
measured 
B. 9.83 
 
 
35 3 days 1 
57, M Cardiac PEA 35 48 
 
 
 
Yes (33h) 120h Present 
 
 
 
1 25.1 (day 1) 
A.VPA 
B.LEV 
C.CLZ 
D.PRO 
E.PGB 
A.1500 
B.2500 
C.5 
D.300mg/h 
E:150m 
A.42 
 
 
 
32 19 days 3 
62, F Pulmonary PEA 8 24 
 
 
 
Yes (24h) 24h Present 
 
 
 
3 17.1 (day 1) 
A.VPA 
B.LEV 
C.TPM 
D.CLZ 
E.Piracetam 
 
A.3600 
B. 4000 
C.225 
D.1 
E.14.4 
A.47 
 
 
 
32 12 days 3 
83, F Cardiac VF 25 40 
 
Yes (64h) 
72h Present 
 
3 
24.5 (day 2) 
A.VPA 
B.LEV 
C.CLZ 
A.1500 
B.1500 
C.1 
A.62 
 
27 
11 days 3 
43, F Cardiac VF 26 32 
 
 
Yes (32h) 
48h Pupils present, not corneal 
 
 
2 
15.2 (day 2) 
A.LEV 
B VPA 
C.TPM 
D.PER 
A.2000 
B.1500 
C.300 
D.6 
A.18.7 
B.62 
C.5.1 
 
 
 
26 12 days 1 
64, F Not known SR Not known 30 
 
 
 
Yes (30h) 
32h Present 
 
 
 
2 
14.5 (day1) 
A.VPA 
B.LEV 
C.PB 
D.TPM 
A.1500 
B.2000 
C.200 
D.300 
A.39 
C.6.2 
 
 
 
34 
23 days 3 
53, M Cardiac PEA 22 28 
 
 
Yes (28h) 30h Present 
 
 
2 20.1 (day 2) 
A.VPA 
B.LEV 
C.TPM 
A.2500 
B.3000 
C.250 
A.85 
 
36 
3 days 1 
 
Table 1: clinical features of 7 patients with early LAS 
Abbreviations: M= male; F= female; VF= ventricular fibrillation; PEA= pulseless electrical activity; SR= sinus rhythm; EEG= electroencephalographic; SSEP= somatosensory evoked potentials; NSE= serum 
neuron specific; VS = vegetative state; VPA= valproate; LEV= levetiracetam; CLZ= clonazepam; TPM= topiramate; PER= perampanel; PB= Phenobarbital, PGB=pregabaline. 
Therapeutic range of AEDs serum levels: VPA= 50-100mg/L; LEV= 12-46 mg/L; TPM= 5-20 mg/L; PB= 10-40 mg/L. Albumin levels 35-52 g/l. 
